| Literature DB >> 35209006 |
Yerlan M Suleimen1,2, Rani A Jose3, Raigul N Suleimen4, Christoph Arenz5, Margarita Ishmuratova6, Suzanne Toppet3, Wim Dehaen3, Aisha A Alsfouk7, Eslam B Elkaeed8, Ibrahim H Eissa9, Ahmed M Metwaly10,11.
Abstract
Two rare 2-phenoxychromone derivatives, 6-demethoxy-4`-O-capillarsine (1) and tenuflorin C (2), were isolated from the areal parts of Artemisia commutata and A. glauca, respectively, for the first time. Being rare in nature, the inhibition potentialities of 1 and 2 against SARS-CoV-2 was investigated using multistage in silico techniques. At first, molecular similarity and fingerprint studies were conducted for 1 and 2 against co-crystallized ligands of eight different COVID-19 enzymes. The carried-out studies indicated the similarity of 1 and 2 with TTT, the co-crystallized ligand of COVID-19 Papain-Like Protease (PLP), (PDB ID: 3E9S). Therefore, molecular docking studies of 1 and 2 against the PLP were carried out and revealed correct binding inside the active site exhibiting binding energies of -18.86 and -18.37 Kcal/mol, respectively. Further, in silico ADMET in addition to toxicity evaluation of 1 and 2 against seven models indicated the general safety and the likeness of 1 and 2 to be drugs. Lastly, to authenticate the binding and to investigate the thermodynamic characters, molecular dynamics (MD) simulation studies were conducted on 1 and PLP.Entities:
Keywords: 2-phenoxychromones; ADMET; Artemisia commutate; COVID-19 Papain-Like Protease; MD simulations; SARS-CoV-2; molecular docking; molecular fingerprints
Mesh:
Substances:
Year: 2022 PMID: 35209006 PMCID: PMC8879996 DOI: 10.3390/molecules27041216
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The chemical structures 6-demethoxy-4`-O-capillarsine (1) and tenuflorin C (2).
Figure 2The co-crystallized ligands of coronavirus proteins and compounds 1 and 2.
Structural properties of compounds 1, 2 and TTT.
| Compound | ALog p | M. W | HBA | HBD | Rotatable Bonds | Rings | Aromatic Rings | MFPSA | Minimum Distance |
|---|---|---|---|---|---|---|---|---|---|
|
| 3.129 | 300.263 | 6 | 2 | 3 | 3 | 2 | 0.302 | 0 |
|
| 2.887 | 316.262 | 7 | 3 | 3 | 3 | 2 | 0.359 | 0 |
|
| 3.647 | 304.386 | 2 | 2 | 3 | 3 | 3 | 0.171 | 0.723 |
Figure 3The results of similarity analysis of compound 1 (A), compound 2 (B).
Fingerprint similarity between compounds 1, 2 and TTT.
| Compound | Similarity | SA | SB | SC |
|---|---|---|---|---|
|
| 1 | 299 | 0 | 0 |
|
| 1 | 289 | 0 | 0 |
|
| 0.579 | 276 | 178 | 23 |
SA: The number bits present in both the isolated 2-phenoxychromone derivative and TTT. SB: The number of bits in the isolated 2-phenoxychromone derivative but not TTT. SC: The number of bits in TTT but not the isolated 2-phenoxychromone derivative.
Figure 4Compounds 1 and 2 have the same pharmacophoric features of the co-crystallized ligand of SARS CoV-2 PLP(TTT).
Figure 5(A) Flexible alignment of compounds 1 (turquoise) TTT (green). (B) Flexible alignment of compounds 2 (turquoise) with TTT (green).
Figure 6Superimposition of the co-crystallized molecule (Turquoise) and the docking pose (dark green) of the same molecule.
Figure 7(A) 3D, (B) 2D and (C) Surface mapping of TTT inside the active site of PLP.
Figure 8(A) 3D, (B) 2D and (C) Surface mapping of 6-demethoxy-4`-O-capillarsine (1) inside the active site of PLP.
Figure 9(A) 3D, (B) 2D, and (C) surface mapping of tenuflorin C (2) inside the active site of PLP.
Figure 10The expected ADMET study.
Binding free energies (∆G in Kcal/mol) of the 6-demethoxy-4`-O-capillarsine (1), tenuflorin C (2) and TTT against PLP.
| Compound | ∆G [Kcal/mol] |
|---|---|
|
| −18.86 |
|
| −18.37 |
|
| −20.32 |
Toxicity properties of compounds.
| Compound | FDA Rodent Carcinogenicity | Carcinogenicity TD50 a | Rat MTD b | Rat Oral LD50 b | LOAEL b | Ocular | Skin |
|---|---|---|---|---|---|---|---|
|
| Not a | 144.939 | 0.289735 | 0.363122 | 0.0221904 | + | - |
|
| Not a | 113.277 | 0.44318 | 0.549081 | 0.0362493 | + | - |
| remdesivir | Not a | 9.2458 | 0.234965 | 0.308859 | 0.0037911 | + | + |
a Unit: mg·kg−1·day−1., b Unit: g·kg−1., c - = nonirritant, + = mild.
Figure 11Molecular dynamics simulations results; (A) RMSD values of 6-demethoxy-4`-O-capillarsine, PLP and 6-demethoxy-4`-O-capillarsine -PLP complex during MD runs. (B) RMSF for PLP in the MD run. (C) Radius of gyration of PLP in the MD run. (D) SASA of PLP in the MD run. (E) H- bonding between 6-demethoxy-4`-O-capillarsine -PLP complex in the MD run.